TOP TEN perturbations for 39377_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39377_at
Selected probe(set): 212145_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39377_at (212145_at) across 6674 perturbations tested by GENEVESTIGATOR:

LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample

Relative Expression (log2-ratio):-3.220623
Number of Samples:2 / 2
Experimental LPS study 4 (shRNA contr.)
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control mock treated / transduced MONO-MAC-6 cell sample
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated.

R547 study 1 (24h) / vehicle (DMSO) treated DU145 cell sample

Relative Expression (log2-ratio):-2.7609577
Number of Samples:2 / 4
Experimental R547 study 1 (24h)
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:---
Control vehicle (DMSO) treated DU145 cell sample
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours.

LPS study 4 / mock treated MONO-MAC-6 cell sample

Relative Expression (log2-ratio):-2.630087
Number of Samples:2 / 2
Experimental LPS study 4
MONO-MAC-6 (MM6) cells were treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control mock treated MONO-MAC-6 cell sample
MONO-MAC-6 (MM6) cells mock treated.

glioma study 16 (LN-18) / normal astrocyte sample

Relative Expression (log2-ratio):2.489933
Number of Samples:2 / 3
Experimental glioma study 16 (LN-18)
Human glioma cell line LN018 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

LPS study 4 (shRNA cycT1) / cycT1 depletion study 2 (shRNA)

Relative Expression (log2-ratio):-2.4094658
Number of Samples:2 / 2
Experimental LPS study 4 (shRNA cycT1)
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control cycT1 depletion study 2 (shRNA)
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then mock treated.

zalypsis study 2 / untreated OPM1 cell sample

Relative Expression (log2-ratio):-2.1235752
Number of Samples:2 / 2
Experimental zalypsis study 2
OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:---
Control untreated OPM1 cell sample
OPM1 multiple myeloma cells untreated.

pediatric septic shock study 3 (infant; subclass A) / normal blood sample (infant)

Relative Expression (log2-ratio):-1.9805374
Number of Samples:8 / 17
Experimental pediatric septic shock study 3 (infant; subclass A)
Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.
Control normal blood sample (infant)
Whole blood samples from infants (1 month – 1 year). Children who had a recent febrile illness (within 2 weeks), who recently used anti-inflammatory medications (within 2 weeks) or who had any history of chronic or acute disease associated with inflammation were excluded from the study.

glioma study 16 (LN-319) / normal astrocyte sample

Relative Expression (log2-ratio):1.8669834
Number of Samples:2 / 3
Experimental glioma study 16 (LN-319)
Human glioma cell line LN319 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

glioma study 16 (LN-229) / normal astrocyte sample

Relative Expression (log2-ratio):1.7448397
Number of Samples:2 / 3
Experimental glioma study 16 (LN-229)
Human glioma cell line LN229 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

expO ovary cancer study 1 (mixed epithelial tumor; primary) / expO ovary cancer study 1 (carcinoma, undifferentiated type, NOS; primary)

Relative Expression (log2-ratio):1.731103
Number of Samples:3 / 2
Experimental expO ovary cancer study 1 (mixed epithelial tumor; primary)
Primary tumor tissue samples obtained from the ovary of patients with mixed epithelial tumor.
Control expO ovary cancer study 1 (carcinoma, undifferentiated type, NOS; primary)
Primary tumor tissue samples obtained from the ovary of patients with carcinoma, undifferentiated type (NOS).